Incyte Corporation (INCY) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Total Cash From Operating Activities Chart for Incyte Corporation

Incyte Corporation (INCY) operating cash flow for FY2025 was USD 1.4B, a 321.5% change from FY2024. Incyte Corporation's operating cash flow moved from USD -4.4M in 1993 to USD 1.4B in 2025 over 32 years. Operating cash flow compound annual growth rate: 10-year CAGR of 32.2%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$24.00B
Implied Share Price
$118.38
Enterprise Value
$19.95B
Revenue (TTM)
$5.82B
EBITDA
$1.94B
Profit Margin
27.71%
Trailing P/E
15.27
Forward P/E
38.76
Price/Book (MRQ)
3.85
Price/Sales (TTM)
4.12
EV/EBITDA
9.65
EV/Revenue
3.43
Dividend Yield
—
Book Value
$31.57
Free Cash Flow (FY2025)
$1.35B
Free Cash Flow Yield
5.65%

Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.